Live feed08:05:00·21hPRReleasevia QuantisnowJohnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel diseaseByQuantisnow·Wall Street's wire, on your screen.JNJ· Johnson & JohnsonHealth Care
